<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317849</url>
  </required_header>
  <id_info>
    <org_study_id>xijing-003</org_study_id>
    <nct_id>NCT01317849</nct_id>
  </id_info>
  <brief_title>China Stroke Secondary Prevention Trial</brief_title>
  <acronym>CSSPT</acronym>
  <official_title>Folic Acid and B Vitamins for Secondary Prevention of Stroke : A Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary
      stroke prevention trial in China to determine whether the addition of folic acid and vitamin
      supplements will reduce recurrent stroke events and other combined incidence of recurrent
      vascular events and vascular death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CSSPT study is a multi-center, randomized, double blinded, placebo-controlled secondary
      stroke prevention trial in China to determine whether the addition of folic acid and vitamin
      supplements will reduce recurrent stroke events and other combined incidence of recurrent
      vascular events and vascular death in patients with recent stroke or transient ischemic
      attack (TIA). All patients presenting to one of the participating neurologists or general
      physicians within one months of stroke (ischemic or hemorrhagic) or TIA (eye or brain) are
      eligible for this trial. Eligible patients will be randomized in a double-blinded fashion to
      receive multi-vitamins or placebo. The primary outcome event is the composite event &quot;stroke,
      myocardial infarction, or death from any vascular cause&quot;, whichever occurs first. Our target
      is to recruit a total of 8,000 patients over the two years with a median follow-up of 3
      years. Recruitment to the trial began in July 2011 and is planned to continue until December
      2013. The investigators aim to complete final follow-up by the end of 2016.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    financial assistance financial assistance financial assistance financial assistance financial
    assistance without financial assistance
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent stroke</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death due to other vascular causes</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TIA</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization procedures</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dementia</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>vitamin supplements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>0.8mg</description>
    <arm_group_label>vitamin supplements</arm_group_label>
    <other_name>folate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B6</intervention_name>
    <description>10mg</description>
    <arm_group_label>vitamin supplements</arm_group_label>
    <other_name>Pyridoxine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>500ug</description>
    <arm_group_label>vitamin supplements</arm_group_label>
    <other_name>Cyanocobalamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.8 mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>10mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>500ug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting within one months of ischemic stroke (ischemic or hemorrhagic) or
             TIA

          -  Homocysteine level ≥ 15μmol／L

          -  Agree to take study medication;Be geographically accessible for follow-up

          -  Provide written informed consent

        Exclusion Criteria:

          -  Other cause of ischemic stroke (cardioembolism; stroke of other determined etiology,
             and stroke of undetermined etiology according to TOAST subtypes) or hemorrhagic stroke
             (intracranial vascular malformations; cerebral amyloid angiopathy; trauma and bleeding
             disorders etc)

          -  Use of vitamin supplements containing folate, B6 or B12

          -  Pregnancy or women of child-bearing potential who are at risk of pregnancy

          -  Limited life expectancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zhao, MD</last_name>
    <role>Study Director</role>
    <affiliation>the Department of Neurology , Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hosptial</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Liu X, Shi M, Xia F, Han J, Liu Z, Wang B, Yang F, Li L, Wu S, Wang L, Liu N, Lv Y, Zhao G. The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke. Int J Stroke. 2015 Feb;10(2):264-8. doi: 10.1111/ijs.12017. Epub 2013 Mar 12.</citation>
    <PMID>23490255</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>folic acid</keyword>
  <keyword>B vitamins</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>stroke</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>homocysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

